congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
Disease Area Tab
PublicationView
Oral
T-DXd
ESMO 2023 | October 20-24, 2023
Efficacy and safety of trastuzumab deruxtecan in patients with solid tumors harboring specific activating HER2 mutations: Primary results from the international phase 2 DESTINY-PanTumor01 study
Poster
Other/Multi
AACR 2024 | April 5-10, 2024
Targeted proteomics and next-generation sequencing (NGS) for biomarker discovery in metastatic colorectal cancer (mCRC)